Tandem Diabetes Care Inc (NASDAQ:TNDM) Expected to Announce Earnings of -$0.08 Per Share

Share on StockTwits

Brokerages expect that Tandem Diabetes Care Inc (NASDAQ:TNDM) will announce earnings of ($0.08) per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Tandem Diabetes Care’s earnings. The highest EPS estimate is $0.06 and the lowest is ($0.21). Tandem Diabetes Care posted earnings of $0.02 per share during the same quarter last year, which would indicate a negative year over year growth rate of 500%. The company is scheduled to issue its next quarterly earnings report on Tuesday, February 25th.

On average, analysts expect that Tandem Diabetes Care will report full year earnings of ($0.58) per share for the current year, with EPS estimates ranging from ($0.68) to ($0.41). For the next year, analysts expect that the business will post earnings of $0.02 per share, with EPS estimates ranging from ($0.30) to $0.50. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings data on Monday, November 4th. The medical device company reported ($0.13) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.07. The business had revenue of $94.66 million during the quarter, compared to analysts’ expectations of $88.46 million. Tandem Diabetes Care had a negative return on equity of 9.44% and a negative net margin of 7.19%.

A number of equities analysts have weighed in on the stock. UBS Group upgraded shares of Tandem Diabetes Care from a “neutral” rating to a “buy” rating and set a $75.00 price objective for the company in a research report on Friday, October 4th. BidaskClub raised shares of Tandem Diabetes Care from a “hold” rating to a “buy” rating in a report on Saturday, November 23rd. Guggenheim started coverage on shares of Tandem Diabetes Care in a research report on Thursday, October 17th. They set a “buy” rating and a $76.00 price target for the company. Finally, ValuEngine downgraded shares of Tandem Diabetes Care from a “sell” rating to a “strong sell” rating in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $75.31.

In related news, CEO John F. Sheridan sold 462 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $70.00, for a total transaction of $32,340.00. Following the completion of the sale, the chief executive officer now owns 2,963 shares of the company’s stock, valued at approximately $207,410. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO John F. Sheridan sold 9,538 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $70.03, for a total transaction of $667,946.14. Following the completion of the sale, the chief executive officer now owns 12,039 shares of the company’s stock, valued at approximately $843,091.17. The disclosure for this sale can be found here. Insiders sold 45,000 shares of company stock valued at $2,988,036 over the last quarter. Company insiders own 6.90% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in Tandem Diabetes Care by 53.3% during the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock worth $30,000 after buying an additional 160 shares in the last quarter. TRUE Private Wealth Advisors purchased a new position in shares of Tandem Diabetes Care during the 2nd quarter worth $33,000. First Quadrant L P CA acquired a new position in shares of Tandem Diabetes Care during the 3rd quarter valued at about $34,000. James Investment Research Inc. boosted its position in shares of Tandem Diabetes Care by 15.9% during the 2nd quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock valued at $85,000 after acquiring an additional 180 shares during the last quarter. Finally, Stephens Inc. AR purchased a new stake in shares of Tandem Diabetes Care in the second quarter valued at about $113,000. Institutional investors and hedge funds own 83.16% of the company’s stock.

Shares of NASDAQ:TNDM traded down $1.86 during midday trading on Friday, reaching $61.88. 1,593,984 shares of the company’s stock traded hands, compared to its average volume of 1,614,355. The company has a fifty day simple moving average of $64.06 and a two-hundred day simple moving average of $64.13. Tandem Diabetes Care has a 1 year low of $29.43 and a 1 year high of $74.81. The company has a market cap of $3.77 billion, a P/E ratio of -24.27 and a beta of 0.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.05 and a current ratio of 2.46.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Read More: What does earnings per share mean?

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

$133.30 Million in Sales Expected for Everi Holdings Inc  This Quarter
$133.30 Million in Sales Expected for Everi Holdings Inc This Quarter
$3.31 Billion in Sales Expected for Infosys Ltd  This Quarter
$3.31 Billion in Sales Expected for Infosys Ltd This Quarter
$349.54 Million in Sales Expected for Dave & Buster’s Entertainment Inc  This Quarter
$349.54 Million in Sales Expected for Dave & Buster’s Entertainment Inc This Quarter
Kinder Morgan  Set to Announce Earnings on Wednesday
Kinder Morgan Set to Announce Earnings on Wednesday
Cohen & Steers  to Release Earnings on Wednesday
Cohen & Steers to Release Earnings on Wednesday
NVE  Set to Announce Quarterly Earnings on Wednesday
NVE Set to Announce Quarterly Earnings on Wednesday


 
© 2006-2020 Zolmax.